Search results
Showing 856 to 870 of 8221 results
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA777)
Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.
Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.
Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults.
Evidence-based recommendations on faricimab (Vabysmo) for diabetic macular oedema in adults.
Faricimab for treating wet age-related macular degeneration (TA800)
Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.
Cemiplimab for treating advanced cutaneous squamous cell carcinoma (TA802)
Evidence-based recommendations on cemiplimab (Libtayo) for metastatic or locally advanced cutaneous squamous cell carcinoma in adults.
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
Evidence-based recommendations on risankizumab (Skyrizi) for treating active psoriatic arthritis in adults.
Evidence-based recommendations on teduglutide (Resvestive) for treating short bowel syndrome in people 1 year and above.
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.
Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over.
NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over. This is because Novartis has confirmed that it does not intend to make an evidence submission for the appraisal.
Show all sections
Sections for TA840
NICE is unable to make a recommendation on carfilzomib (Kyprolis) with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma in adults. This is because Amgen did not provide an evidence submission.
Show all sections
Sections for TA841
NICE is unable to make a recommendation on tisagenlecleucel (Kymriah) for treating relapsed or refractory follicular lymphoma in adults after 2 or more therapies. This is because Novartis did not provide an evidence submission.
Show all sections
Sections for TA842
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal) (TA843)
NICE is unable to make a recommendation on luspatercept (Reblozyl) for treating anaemia caused by beta-thalassaemia because BMS did not provide an evidence submission.
Show all sections
Sections for TA843